Development and validation of a comprehensive patient‐specific quality assurance program for a novel stereotactic radiation delivery system for breast lesions. Issue 12 (13th December 2019)

• Record Type: Journal Article
• Authors: Becker, Stewart J.; Niu, Ying; Mutaf, Yildirim; Chen, Shifeng; Poirier, Yannick; Nichols, Elizabeth M.; Yi, ByongYong
• Is Part Of: Journal of applied clinical medical physics. Volume 20:Issue 12(2019)
• Page Start: 138
• Page End: 148
• Publication Date: 2019-12-13
• Subjects: breast -- commissioning -- patient specific quality assurance -- stereotactic radiosurgery; Medical physics -- Periodicals; Clinical medicine -- Periodicals; Health Physics; Clinical Medicine; Electronic journals; Periodicals; Periodicals; Fulltext; Internet Resources; 610.153
• DOI: 10.1002/acm2.12778
• Languages: English
• ISSNs: 1526-9914

Abstract

Abstract: Purpose: The GammaPod is a dedicated prone breast stereotactic radiosurgery (SRS) machine composed of 25 cobalt‐60 sources which rotate around the breast to create highly conformal dose distributions for boosts, partial‐breast irradiation, or neo‐adjuvant SRS. We describe the development and validation of a patient‐specific quality assurance (PSQA) system for the GammaPod. Methods: We present two PSQA methods: measurement based and calculation based PSQA. The measurements are performed with a combination of absolute and relative dose measurements. Absolute dosimetry is performed in a single point using a 0.053‐cc pinpoint ionization chamber in the center of a polymethylmethacrylate (PMMA) breast phantom and a water‐filled breast cup. Relative dose distributions are verified with EBT3 film in the PMMA phantom. The calculation‐based method verifies point doses with a novel semi‐empirical independent‐calculation software. Results: The average (± standard deviation) breast and target sizes were 1263 ± 335.3 cc and 66.9 ± 29.9 cc, respectively. All ion chamber measurements performed in water and the PMMA phantom agreed with the treatment planning system (TPS) within 2.7%, with average (max) difference of –1.3% (−1.9%) and −1.3% (−2.7%), respectively. Relative dose distributions measured by film showed an average gamma pass rate of 97.0 ± 3.2 when using a 3%/1 mm criteria. The lowest gamma analysis pass rate was 90.0%. The independent calculation software had average agreements (max) with the patient and QA plan calculation of 0.2% (2.2%) and −0.1% (2.0%), respectively. Conclusion: We successfully implemented the first GammaPod PSQA program. These results show that the GammaPod can be used to calculate and deliver the predicted dose precisely and accurately. For routine PSQA performed prior to treatments, the independent calculation is recommended as it verifies the accuracy of the planned dose without increasing the risk of losing vacuum due to prolonged waiting times.